Skip to main content
OpenTrials
Completed

NCT Number: NCT00711893

Feature Assessment Study for Indications Based Programming

The purpose of this evaluation is to assess the acceptance level of specific programming recommendations based on the patient's clinical needs and primary indications when using the feature 'Indications Based Programming' (IBP) available in the ZOOMVIEW Software Application for the TELIGEN DR / VR and COGNIS family of devices compared to daily life programming chosen by physicians.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

KH der Elisabethinen Linz, Linz, Austria

Loading trial locations.

About this study

"This study will focus on documenting the final parameter changes that are made in comparison to the IBP recommendations for a specific cardiovascular and arrhythmia history. It will therefore compare the device settings that were finally programmed during the last available follow up procedure to the last available parameter recommendations of IBP. IBP was designed to facilitate programming by providing customized parameter settings based on a patient's clinical needs and primary indication.

In order to further enhance the IBP feature for future device generations, additional data may be collected and evaluated on:

  • Physician perception and satisfaction with the New User Interface (NUI) of the programming application;
  • Motivation for adapting IBP recommendations for the final programming of the device;
  • Device data that can be retrieved from patient data disks that may include but is not limited to, arrhythmia episode detail, pacing counter data; total and individual therapy data"

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • indicated for implantation of an ICD or CRT-D device according local hospital implant criteria guidelines
  • Implanted or intended to be implanted with any CE-marked device approved for implant from the TELIGEN (single or dual chamber ICD) or COGNIS (CRT-D) family during first implant (no replacements)
  • Geographically stable patients who are available for follow-up at a study centre
  • Age 18 or above, or of legal age to give informed consent specific to national law

Exclusion criteria

Inability or refusal to sign the Patient Informed Consent

  • Pregnant or planning to become pregnant
  • Replacement device
  • Enrolment in another clinical trial, study or evaluation
  • Estimated life expectancy of less than six months per discretion of physician

Treatment and study plan

Cognis 100-D, Teligen DR and VR 100 HE

Device

Teligen is an implantable defibrillator for detection and termination of life threatening arrhythmias. Cognis includes in addition to these capabilities cardiac resynchronization therapy for patients having heart failure.

Primary outcomes

  1. Proportion of patients that are programmed by the physician to anything other than the recommended IBP setting

    Time frame: 6 Months

Secondary outcomes

  1. - Degree of acceptance of IBP - Proportion parameters changed per patient - Differences between recommended and final programmed parameters - Total number of parameter changes from IBP recommendations - Frequency of changes made to a single parameter

    Time frame: 6 Months

Sponsors and collaborators

Lead sponsor

Boston Scientific Corporation

Industry

Collaborators

  • Guidant Corporation

Registry information

Acronym: FASt-IBP

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Jul 9, 2008
Registry last updated
Feb 23, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.